Future Patients: Why Procurement Matters In Emerging Life Sciences

By Tom Wells

Most emerging life sciences companies already understand the importance of thinking about the future patient. 

Leadership teams routinely model future treatment pathways, reimbursement environments, and healthcare system evolution years before launch. They work with market access specialists, commercialization advisors, health economics experts, and patient insight consultancies to understand how therapies may ultimately be prescribed, funded, and used in the real world.

The challenge for modern biotech is therefore no longer recognizing the importance of patient centricity — the challenge is operationalizing it.

That’s because many of the decisions that ultimately determine whether future patients can successfully access, use, and remain adherent to a therapy are embedded much earlier than many organizations realize — often during the transition from scientific innovation to Series A and B growth.

This is the point at which companies begin defining operating models, selecting strategic suppliers, outsourcing critical capabilities, and deploying significant investment capital. Choices made during this phase frequently become embedded in the organization’s long-term structure and commercial model.

For leadership teams focused primarily on advancing the science, procurement may be perceived as largely functional: a mechanism for sourcing capability and controlling cost. But that view increasingly underestimates its strategic importance.

At its best, procurement is not simply purchasing. It is the operational discipline through which organizations translate future-patient strategy into scalable reality.

It is through procurement that organizations shape supplier ecosystems; determine resilience and flexibility, and build them into commercial arrangements; assess long-term operational risk; and determine how therapies will ultimately reach — and remain accessible to — future patients.

From Future-Patient Insight To Operational Reality

The questions biotech leaders need to ask are clear.

What will the healthcare environment look like when the therapy reaches market? How will reimbursement systems evolve? Will care pathways become more decentralized? How will digital integration, homecare, and workforce shortages reshape treatment delivery?

Similarly, organizations increasingly understand that future patient populations may differ significantly in age, mobility, digital confidence, socioeconomic circumstances and caregiver support.

These are no longer niche considerations. They are central to commercial planning and investor discussions across the industry.

What is less frequently recognized is how profoundly these assumptions should influence operational decision-making much earlier in development.

For example, an elderly patient population with reduced dexterity may require a therapy that is ergonomically simple and supported by homecare infrastructure; low income, rural patients of all ages may require support with transport to specialist centres; younger, digitally confident patients may benefit from entirely different delivery and support models. 

This has implications far beyond patient communications or support programs.

Decisions around dosage formulation, for example, may shape long-term adherence and accessibility as much as clinical efficacy. The optimal future solution may involve oral delivery, self-injection, inhalation, patch-based administration, or clinic-based infusion depending on the realities of how patients will live and interact with healthcare systems.

Similarly, device usability may prove critical to real-world outcomes. A delivery device that performs effectively during development may become difficult or intimidating for patients with arthritis, impaired vision, or limited health literacy. Packaging and onboarding processes that assume high digital confidence or fluent English-language comprehension may unintentionally exclude parts of the intended patient population.

Importantly, once these assumptions become embedded into development pathways, supplier relationships, and operating models, they become progressively harder and more expensive to change.

Identifying The Risks Early

The good news for emerging organizations is that future-patient operational planning does not necessarily require large internal teams or highly complex transformation programs.

Many organizations already possess access to the strategic insight required. The key challenge is ensuring that those insights are systematically translated into operational design and supplier strategy.

One useful exercise is the creation of evidence-based future patient personas that move beyond broad demographic assumptions and consider practical realities such as mobility, treatment confidence, digital literacy, caregiver support, and socioeconomic circumstances. The value lies not simply in understanding future patients conceptually, but in testing whether proposed operating models are realistically capable of supporting them.

A second exercise is to model how healthcare delivery itself may evolve across target markets over the next decade. In many countries, care pathways are already shifting toward home-based treatment, digitally enabled monitoring, and increasingly constrained clinical capacity. Regulatory expectations and reimbursement pressures are evolving rapidly as well. These trends may materially influence formulation choices, logistics requirements, service models, and supplier capability needs.

A third exercise is to map potential barriers to patient access and persistence early in development. Transport limitations, clinic availability, cold-chain dependence, language barriers, low health literacy, or limited confidence with digital onboarding may all become operational constraints later if they are not identified early enough.

Taken together, these exercises help organizations understand not simply what future success may look like, but where future operational fragility may emerge.

Procurement As Ecosystem Architect

This is where procurement becomes strategically central.

Delivering a patient-centric therapy depends upon far more than manufacturing capability alone. It often requires a highly interconnected ecosystem of formulation specialists, device manufacturers, packaging providers, logistics and cold-chain partners, homecare services, digital health platforms, and specialist regulatory expertise.

Procurement increasingly acts as the mechanism through which these external capabilities are identified, evaluated, and integrated into a coherent operating model.

That changes the nature of supplier evaluation fundamentally.

The question is no longer simply whether a supplier can meet current technical requirements or provide short-term cost efficiency. Organizations increasingly need to assess whether suppliers can support future scalability, adapt to evolving healthcare models, and contribute to long-term operational resilience.

Questions around usability, interoperability, manufacturing flexibility, and geopolitical exposure therefore become directly relevant to future patient access and commercial success.

Commercial structures matter equally. Agreements established during early growth phases frequently persist well into commercialization. Contracts therefore need to balance stability with flexibility, allowing organizations to adapt as technologies, reimbursement systems, and healthcare delivery models evolve over time.

In this context, procurement becomes far less about transactional purchasing and far more about shaping long-term operational capability.

Building Investor-Ready Operational Resilience

Future-patient operational planning also naturally connects to supply-chain resilience and investor confidence.

Recent years have demonstrated how geopolitical instability, regulatory fragmentation, pandemics, and inflationary pressures can rapidly destabilize global supply networks. For life sciences companies, these risks are not merely operational concerns — they may directly affect continuity of patient access.

Therapies that depend upon fragile single-source arrangements, geographically concentrated manufacturing or highly specialized logistics infrastructure may face significant future vulnerabilities. Organizations that identify these risks early are often better positioned to build resilience into supplier ecosystems, manufacturing strategies, and commercial partnerships from the outset.

Investors are increasingly scrutinizing these capabilities as well. Operational maturity, scalability and ecosystem resilience are becoming as important as scientific promise alone. The ability to demonstrate thoughtful approaches to future patient access, supplier robustness, and long-term execution capability may increasingly differentiate organizations in competitive capital markets.

The goal for emerging companies is not necessarily to build large procurement functions prematurely. Rather, it is to recognize procurement as a strategic capability earlier than many organizations traditionally have. During the critical Series A to B transition, operational complexity often accelerates faster than internal infrastructure. Access to experienced operational and procurement leadership — whether internal, external, or fractional — can help organizations establish scalable supplier ecosystems and avoid strategic missteps before they become deeply embedded.

The most successful life sciences organizations of the next decade are unlikely to be defined solely by the quality of their science. They will increasingly be distinguished by their ability to translate future-patient insight into resilient operational reality.

Procurement sits at the centre of that challenge. And for companies scaling through the critical early-growth phase, it may become one of the most important strategic enablers of all.

About The Author:

Tom Wells leads Agar Advisory, a UK-based firm providing sourcing, supply chain and procurement support for early-stage life sciences firms. Click here to watch Tom discuss procurement issues on the Business of Biotech.